SCHEMBL7336298

SCHEMBL7336298

N=C(N)c1ccc2cc(C(=O)Nc3ccc4c(c3)OCO4)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 6/20 1.00
▸ NPC1 O15118 11/20 0.71
▸ RAB9A P51151 11/20 0.71
▸ SMN1; SMN2 Q16637 5/20 0.71
▸ MAPT P10636 4/20 0.71
▸ PKM P14618 2/20 0.71
▸ ALDH1A1 P00352 1/20 0.71
▸ NFKB1 P19838 1/20 0.71
▸ NFKB2 Q00653 1/20 0.71
▸ RELA Q04206 1/20 0.71
▸ CASP3 P42574 5/20 0.64
▸ SENP7 Q9BQF6 5/20 0.64
▸ PLG P00747 4/20 0.64
▸ KLKB1 P03952 4/20 0.64
▸ PRSS1 P07477 4/20 0.64
▸ F2 P00734 3/20 0.64
▸ TP53 P04637 2/20 0.61
▸ PLAT P00750 3/20 0.60
▸ KLK1 P06870 1/20 0.60
▸ SENP8 Q96LD8 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13561178 0.86 NPC1 (0.76) PLAUNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL108116 0.84 NPC1 (1.00) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL7150673 0.83 PLAU (0.70) PLAUNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL27179668 0.82 RAB9A (0.90) NPC1RAB9ASMN1; SMN2MAPTPKM
SCHEMBL7336307 0.80 PLAU (0.67) PLAUNPC1RAB9ASMN1; SMN2MAPT
Trifluoroacetic Acid SCHEMBL6296021 0.79 PLAU (0.63) PLAUNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL7335930 0.79 PLAU (0.78) PLAUNPC1RAB9ACASP3SENP7
SCHEMBL18941082 0.79 RAB9A (0.78) PLAUNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL7340321 0.78 PLAU (1.00) PLAUPLGKLKB1PRSS1F2
SCHEMBL3033609 0.78 NPC1 (0.69) PLAUNPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 — — US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 — — US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 — — US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 — — EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885NPC1 2478/4885RAB9A 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback